AZ-EDGIO
7.2.2024 12:01:32 CET | Business Wire | Press release
Edgio, the platform of choice for speed, security, and simplicity at the edge, today announced a partnership with KPS, the leading partner for customer-centric business transformation. KPS is known for implementing best-of-breed, agile technology that increases website conversion, customer loyalty, and revenue per client.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240207602775/en/
To meet increasingly demanding consumer expectations, KPS’s enterprise retail clients require the flexibility, scalability, agility, speed-to-market and cost efficiency that a composable web architecture provides. With a modular approach at its core, composable commerce enables brands to select best-of-breed solutions and customize a tech stack that more closely reflects their unique business requirements.
After reviewing the market for a technology partner to support them, KPS chose Edgio to help accelerate that composability evolution for their clients. Edgio’s Sites solution enables companies to develop front-end applications at the edge with ease, using 40+ frameworks with automated deployment.
Edgio’s patented iterative migration approach will now allow KPS to evolve their clients’ applications to become headless and more composable over time, rather than through costly one-off implementations, proving value and return at every stage.
Alongside headless capabilities, all the features of the Edgio Applications platform – dynamic caching, real-time customer experience monitoring, predictive prefetching, and best-of-breed security solutions, are easily accessible via fixed-price bundles that can be purchased at an entry level that makes sense to each individual client. This is a game changer for KPS as it means they can offer clients a competitive pricing model that scales with their business growth.
“It's an exciting relationship for KPS, building on our principles of quality, security, and performance that allow us to provide more composable and future-proofed solutions. It provides our clients access to best-of-breed security and online experience capabilities,” said Tim Hillman, CTO (UK) at KPS. "We are delighted to collaborate with Edgio, a team of highly skilled and experienced security and application experts. Their unwavering commitment to KPS and our clients is evident in their exceptional dedication and support. We look forward to strengthening our trusted partnership and we eagerly anticipate the innovative solutions Edgio will bring to our clients in the future.”
“With over two decades of experience creating unique digital solutions and exceptional customer experience, KPS is known for helping companies implement best-of-breed technology,” said Emma Whitmore, Group Vice President, EMEA at Edgio. "We are thrilled to be partnering with KPS to deploy high-performing, brand-building experiences that delight their customers. Aligning our security and performance technology with their industry know-how and passion for successful transformations, will mean their retail clients can innovate and adapt quickly to changing business needs.”
About Edgio
Edgio (NASDAQ: EGIO) helps companies deliver online experiences and content faster, safer, and with more control. Its developer-friendly, globally scaled edge network, combined with fully integrated application and media solutions, provides a single platform for the delivery of high-performing, secure web properties and streaming content. Through this fully integrated platform and end-to-end edge services, companies can deliver content quicker and more securely, thus boosting overall revenue and business value. To learn more, visit edg.io and follow us on Twitter, LinkedIn, and Facebook.
About KPS
KPS specialises in composable commerce across the entire customer journey, from app, loyalty and data insights to marketplaces, multichannel retailing and digital growth. Working with leading consumer and business-to-business brands as a trusted partner, KPS creates enduring value by understanding customers, their needs and behaviour, to deliver truly engaging experiences in a rapidly changing environment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207602775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom